DailyIQ
|
Sector:HealthcareAll sectors
Last updated 100 days ago

ILMN·ILMN

$.
+. (+.%)
High
$117.47
Open
$115.19
Market Cap
17.85B
52W High
$155.53
Low
$114.94
P. Close
$114.45
P/E
21.00
52W Low
$68.70
Fwd P/E
-
Mean Target
-
Technical Score (1D)
32
SELL
News Sentiment
55
BULLISH
Illumina's Q4 earnings and revenue surpassed estimates, fueled by robust demand for clinical consumables, particularly outside of China. This strong performance, including a 5% year-over-year revenue increase and a 42% rise in non-GAAP EPS, is driving the company's positive guidance for 2026. The company is also transitioning to the NovaSeq X platform, with expectations for substantial completion by the end of 2026. However, despite the positive financial results, the stock price declined due to investor concerns about gross margin contraction. Some analysts are also questioning the sustainability of growth and the underlying earnings power, suggesting that unusual items may have inflated profits. While the company is expanding its multiomics portfolio and clinical partnerships, the market's reaction has been mixed. Several analysts have adjusted their price targets, with some maintaining a positive outlook and others adopting a more cautious stance. Investors should watch for continued clinical consumables growth and the successful transition to the NovaSeq X platform.
Earnings Summary
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis, operating within the diagnostics & research industry. The company offers instruments, consumables, and services for genomic research. In Q1 2025, Illumina's EPS was $0.97, exceeding the estimate of $0.93, with revenue at $1.041 billion. The next reported quarter, Q1 2026, has an EPS estimate of $1.05864, with a revenue estimate of $1.073 billion. The company's recent performance shows a positive trend in EPS, with revenue growth. Illumina beat estimates in the last quarter reported. The company's Q4 2025 earnings and revenue exceeded expectations, driven by strong clinical consumables demand, especially outside of China, and NovaSeq X instrument placements. The company's 2026 revenue guidance is between $4.5 and $4.6 billion, indicating continued growth. Recent news highlights strong clinical consumables growth and the positive impact of NovaSeq X instrument placements. Investors should watch for continued adoption of sequencing-based tests and the impact of the NovaSeq X platform transition, as well as developments in international markets.

EPS

EstBeatMiss
$0.92$0.96$1.00$1.04$1.08Q1'25Q1'26
QtrEstActual+/−
Q1'26$1.06 - -
Q1'25$0.94$0.97+3.3%

Revenue

EstBeatMiss
$1.0B$1.0B$1.1B$1.1B$1.1BQ1'25Q1'26
QtrEstActual+/−
Q1'26$1.1B - -
Q1'25 - $1.0B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ILMN Stock Snapshot

ILMN is currently trading at $116.30, giving ILMN a market cap of 17.85B and a P/E ratio of 21.0. Today's range spans $114.94–$117.47, with shares opening at $115.19 and moving up $1.85 (1.6%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 55/100.

Over the past year ILMN has traded between $68.70 and $155.53 - the current price is +69.3% off the 52-week low and -25.2% from the high.

ILMN is showing a SELL signal (32/100) with neutral sentiment (55/100). Price: $116.30 (in the middle of its 52-week range within $68.70–$155.53). (P/E: 21.0) At 17.85B in Healthcare market cap, a bearish technical read accompanied by negative sentiment often marks the beginning of an earnings revision cycle downward - active managers trim before the revisions become consensus, compounding the selling pressure.

When a large-cap Healthcare name with 17.85B in capitalization prints a SELL signal (32/100) alongside neutral news sentiment (55/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $116.30 (in the middle of its 52-week range in the $68.70–$155.53 range), the structural support levels are where that sponsorship question gets answered.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

0+ articles
Loading latest news…